TY - JOUR AU - Baron, R. AU - Hesse, E. PY - 2012 DA - 2012// TI - Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives JO - J. Clin. Endocrinol. Metab. VL - 97 UR - https://doi.org/10.1210/jc.2011-2332 DO - 10.1210/jc.2011-2332 ID - Baron2012 ER - TY - JOUR AU - Lee, J. W. PY - 2010 DA - 2010// TI - Alisol-B, a novel phytosteroid, suppresses the RANKL-induced osteoclast formation and prevents bone loss in mice JO - Biochem. Pharmacol. VL - 80 UR - https://doi.org/10.1016/j.bcp.2010.04.014 DO - 10.1016/j.bcp.2010.04.014 ID - Lee2010 ER - TY - JOUR AU - Troen, B. R. PY - 2003 DA - 2003// TI - Molecular mechanisms underlying osteoclast formation and activation JO - Exp. Gerontol. VL - 38 UR - https://doi.org/10.1016/S0531-5565(03)00069-X DO - 10.1016/S0531-5565(03)00069-X ID - Troen2003 ER - TY - JOUR AU - Nanes, M. S. AU - Kallen, C. B. PY - 2014 DA - 2014// TI - Osteoporosis JO - Sem. Nucl. Med. VL - 44 UR - https://doi.org/10.1053/j.semnuclmed.2014.06.006 DO - 10.1053/j.semnuclmed.2014.06.006 ID - Nanes2014 ER - TY - JOUR AU - Kimachi, K. AU - Kajiya, H. AU - Nakayama, S. AU - Ikebe, T. AU - Okabe, K. PY - 2011 DA - 2011// TI - Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis JO - Naunyn Schmiedebergs Arch. Pharmacol. VL - 383 UR - https://doi.org/10.1007/s00210-010-0596-4 DO - 10.1007/s00210-010-0596-4 ID - Kimachi2011 ER - TY - JOUR AU - Suda, T. AU - Takahashi, N. AU - Martin, T. J. PY - 1992 DA - 1992// TI - Modulation of osteoclast differentiation JO - Endocr. Rev. VL - 13 ID - Suda1992 ER - TY - JOUR AU - Lacey, D. PY - 1998 DA - 1998// TI - Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation JO - Cell VL - 93 UR - https://doi.org/10.1016/S0092-8674(00)81569-X DO - 10.1016/S0092-8674(00)81569-X ID - Lacey1998 ER - TY - JOUR AU - Yasuda, H. PY - 1998 DA - 1998// TI - Osteoclast differentiation factor is a ligand for osteoprotegerin osteoclastogenesis inhibitory factor and is identical to TRANCE/RANKL JO - Proc. Natl. Acad. Sci. USA. VL - 95 UR - https://doi.org/10.1073/pnas.95.7.3597 DO - 10.1073/pnas.95.7.3597 ID - Yasuda1998 ER - TY - JOUR AU - Arai, F. PY - 1999 DA - 1999// TI - Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors JO - J. Exp. Med. VL - 190 UR - https://doi.org/10.1084/jem.190.12.1741 DO - 10.1084/jem.190.12.1741 ID - Arai1999 ER - TY - JOUR AU - Ishida, N. PY - 2002 DA - 2002// TI - Large Scale Gene Expression Analysis of Osteoclastogenesis in Vitro and Elucidation of NFAT2 as a Key Regulator JO - J. Biol. Chem. VL - 277 UR - https://doi.org/10.1074/jbc.M205063200 DO - 10.1074/jbc.M205063200 ID - Ishida2002 ER - TY - JOUR AU - Johnson, R. S. AU - Spiegelman, B. M. AU - Papaioannou, V. PY - 1992 DA - 1992// TI - Pleiotropic effects of a null mutation in the c-fos proto-oncogene JO - Cell VL - 71 UR - https://doi.org/10.1016/0092-8674(92)90592-Z DO - 10.1016/0092-8674(92)90592-Z ID - Johnson1992 ER - TY - JOUR AU - Takayanagi, H. PY - 2002 DA - 2002// TI - Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal 1differentiation of osteoclasts JO - Dev. Cell. VL - 3 UR - https://doi.org/10.1016/S1534-5807(02)00369-6 DO - 10.1016/S1534-5807(02)00369-6 ID - Takayanagi2002 ER - TY - JOUR AU - Xing, L. AU - Xiu, Y. AU - Boyce, B. F. PY - 2012 DA - 2012// TI - Osteoclast fusion and regulation by RANKL-dependent and independent factors JO - World J. Orthop. VL - 3 UR - https://doi.org/10.5312/wjo.v3.i12.212 DO - 10.5312/wjo.v3.i12.212 ID - Xing2012 ER - TY - JOUR AU - Kukita, T. PY - 2004 DA - 2004// TI - RANKL-induced DC-STAMP is essential for osteoclastogenesis JO - J. Exp. Med. VL - 200 UR - https://doi.org/10.1084/jem.20040518 DO - 10.1084/jem.20040518 ID - Kukita2004 ER - TY - JOUR AU - Burgess, T. L. PY - 1999 DA - 1999// TI - The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts JO - J. Cell Biol. VL - 145 UR - https://doi.org/10.1083/jcb.145.3.527 DO - 10.1083/jcb.145.3.527 ID - Burgess1999 ER - TY - JOUR AU - Blair, H. C. AU - Teitelbaum, S. L. AU - Ghiselli, R. AU - Gluck, S. PY - 1989 DA - 1989// TI - Osteoclastic bone resorption by a polarized vacuolar proton pump JO - Science VL - 245 UR - https://doi.org/10.1126/science.2528207 DO - 10.1126/science.2528207 ID - Blair1989 ER - TY - JOUR AU - Boyle, W. J. AU - Simonet, W. S. AU - Lacey, D. L. PY - 2003 DA - 2003// TI - Osteoclast differentiation and activation JO - Nature VL - 423 UR - https://doi.org/10.1038/nature01658 DO - 10.1038/nature01658 ID - Boyle2003 ER - TY - JOUR AU - Wada, T. AU - Nakashima, T. AU - Hiroshi, N. AU - Penninger, J. M. PY - 2006 DA - 2006// TI - RANKL-RANK signaling in osteoclastogenesis and bone disease JO - Trends Mol. Med. VL - 12 UR - https://doi.org/10.1016/j.molmed.2005.11.007 DO - 10.1016/j.molmed.2005.11.007 ID - Wada2006 ER - TY - JOUR AU - Mundy, G. R. PY - 2007 DA - 2007// TI - Osteoporosis and inflammation JO - Nutr. Rev. VL - 65 UR - https://doi.org/10.1301/nr.2007.dec.S147-S151 DO - 10.1301/nr.2007.dec.S147-S151 ID - Mundy2007 ER - TY - JOUR AU - Romas, E. AU - Gillespie, M. T. PY - 2006 DA - 2006// TI - Inflammation-induced bone loss: can it be prevented? JO - Rheum. Dis. Clin. North Am. VL - 32 UR - https://doi.org/10.1016/j.rdc.2006.07.004 DO - 10.1016/j.rdc.2006.07.004 ID - Romas2006 ER - TY - JOUR AU - Janciauskiene, S. M. PY - 2011 DA - 2011// TI - The discovery of alpha1-antitrypsin and its role in health and disease JO - Respir. Med. VL - 105 UR - https://doi.org/10.1016/j.rmed.2011.02.002 DO - 10.1016/j.rmed.2011.02.002 ID - Janciauskiene2011 ER - TY - JOUR AU - Lu, Y. Q. PY - 2006 DA - 2006// TI - Alpha(1)-antitrypsin gene therapy modulates cellular immunity and efficiently prevents type 1 diabetes in nonobese diabetic mice JO - Hum. Gene Ther. VL - 17 UR - https://doi.org/10.1089/hum.2006.17.625 DO - 10.1089/hum.2006.17.625 ID - Lu2006 ER - TY - JOUR AU - Ma, H. PY - 2010 DA - 2010// TI - Intradermal alpha1-antitrypsin therapy avoids fatal anaphylaxis, prevents type 1 diabetes and reverses hyperglycaemia in the NOD mouse model of the disease JO - Diabetologia VL - 53 UR - https://doi.org/10.1007/s00125-010-1829-2 DO - 10.1007/s00125-010-1829-2 ID - Ma2010 ER - TY - JOUR AU - Song, S. PY - 2004 DA - 2004// TI - Recombinant adeno-associated virus-mediated alpha-1 antitrypsin gene therapy prevents type I diabetes in NOD mice JO - Gene Ther. VL - 11 UR - https://doi.org/10.1038/sj.gt.3302156 DO - 10.1038/sj.gt.3302156 ID - Song2004 ER - TY - JOUR AU - Grimstein, C. PY - 2011 DA - 2011// TI - Alpha-1 antitrypsin protein and gene therapies decrease autoimmunity and delay arthritis development in mouse model JO - J. Transl. Med. VL - 9 UR - https://doi.org/10.1186/1479-5876-9-21 DO - 10.1186/1479-5876-9-21 ID - Grimstein2011 ER - TY - JOUR AU - Grimstein, C. PY - 2010 DA - 2010// TI - Combination of alpha-1 antitrypsin and doxycycline suppresses collagen-induced arthritis JO - J. Gene Med. VL - 12 UR - https://doi.org/10.1002/jgm.1409 DO - 10.1002/jgm.1409 ID - Grimstein2010 ER - TY - JOUR AU - Shapiro, L. AU - Pott, G. B. AU - Ralston, A. H. PY - 2001 DA - 2001// TI - Alpha-1-antitrypsin inhibits human immunodeficiency virus type 1 JO - FASEB J. VL - 15 UR - https://doi.org/10.1096/fj.00-0311com DO - 10.1096/fj.00-0311com ID - Shapiro2001 ER - TY - JOUR AU - Akbar, M. A. PY - 2016 DA - 2016// TI - Alpha-1 Antitrypsin Gene Therapy Ameliorates Bone Loss in Ovariectomy-Induced Osteoporosis Mouse Model JO - Hum. Gene Ther. VL - 27 UR - https://doi.org/10.1089/hum.2016.029 DO - 10.1089/hum.2016.029 ID - Akbar2016 ER - TY - JOUR AU - Akbar, M. A. PY - 2016 DA - 2016// TI - Transplantation of Adipose Tissue-Derived Mesenchymal Stem Cell (ATMSC) Expressing Alpha-1 Antitrypsin Reduces Bone Loss in Ovariectomized Osteoporosis Mice JO - Hum. Gene Ther. VL - 28 UR - https://doi.org/10.1089/hum.2016.069 DO - 10.1089/hum.2016.069 ID - Akbar2016 ER - TY - JOUR AU - Takahashi, N. AU - Udagawa, N. AU - Kobayashi, Y. AU - Suda, T. PY - 2007 DA - 2007// TI - Generation of osteoclasts in vitro, and assay of osteoclast activity JO - Methods Mol. Med. VL - 135 UR - https://doi.org/10.1007/978-1-59745-401-8_18 DO - 10.1007/978-1-59745-401-8_18 ID - Takahashi2007 ER - TY - JOUR AU - Collin-Osdoby, P. AU - Yu, X. AU - Zheng, H. AU - Osdoby, P. PY - 2003 DA - 2003// TI - RANKL-mediated osteoclast formation from murine RAW 264.7 cells JO - Methods Mol. Med. VL - 80 ID - Collin-Osdoby2003 ER - TY - JOUR AU - Bergin, D. A. PY - 2014 DA - 2014// TI - The circulating proteinase inhibitor alpha-1 antitrypsin regulates neutrophil degranulation and autoimmunity JO - Sci. Transl. Med. VL - 6 UR - https://doi.org/10.1126/scitranslmed.3007116 DO - 10.1126/scitranslmed.3007116 ID - Bergin2014 ER - TY - JOUR AU - Zou, W. AU - Hakim, I. AU - Tschoep, K. AU - Endres, S. AU - Bar-Shavit, Z. PY - 2001 DA - 2001// TI - Tumor necrosis factor-alpha mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism JO - J. Cell. Biochem. VL - 83 UR - https://doi.org/10.1002/jcb.1202 DO - 10.1002/jcb.1202 ID - Zou2001 ER - TY - JOUR AU - Arai, A. PY - 2012 DA - 2012// TI - Fos plays an essential role in the upregulation of RANK expression in osteoclast precursors within the bone microenvironment JO - J. Cell Sci. VL - 125 UR - https://doi.org/10.1242/jcs.099986 DO - 10.1242/jcs.099986 ID - Arai2012 ER - TY - JOUR AU - Petrache, I. AU - Hajjar, J. AU - Campos, M. PY - 2009 DA - 2009// TI - Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency JO - Biologics VL - 3 ID - Petrache2009 ER - TY - JOUR AU - Mohanka, M. AU - Khemasuwan, D. AU - Stoller, J. K. PY - 2012 DA - 2012// TI - A review of augmentation therapy for alpha-1 antitrypsin deficiency JO - Expert Opin. Biol. Ther. VL - 12 UR - https://doi.org/10.1517/14712598.2012.676638 DO - 10.1517/14712598.2012.676638 ID - Mohanka2012 ER - TY - JOUR AU - Hough, F. PY - 2014 DA - 2014// TI - The safety of osteoporosis medication JO - S. Afr. Med. J. VL - 104 UR - https://doi.org/10.7196/SAMJ.7505 DO - 10.7196/SAMJ.7505 ID - Hough2014 ER - TY - JOUR AU - Zou, W. AU - Amcheslavsky, A. AU - Takeshita, S. AU - Drissi, H. AU - Bar-Shavit, Z. PY - 2005 DA - 2005// TI - TNF-α expression is transcriptionally regulated by RANK ligand JO - J. Cell. Physiol. VL - 202 UR - https://doi.org/10.1002/jcp.20127 DO - 10.1002/jcp.20127 ID - Zou2005 ER - TY - JOUR AU - Bergin, D. A. PY - 2010 DA - 2010// TI - alpha-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8 JO - J. Clin. Invest. VL - 120 UR - https://doi.org/10.1172/JCI41196 DO - 10.1172/JCI41196 ID - Bergin2010 ER - TY - JOUR AU - Zhang, B. PY - 2007 DA - 2007// TI - α1-Antitrypsin protects β-cells from apoptosis JO - Diabetes VL - 56 UR - https://doi.org/10.2337/db06-1273 DO - 10.2337/db06-1273 ID - Zhang2007 ER - TY - JOUR AU - Yao, G. Q. AU - Itokawa, T. AU - Paliwal, I. AU - Insogna, K. PY - 2005 DA - 2005// TI - CSF-1 induces fos gene transcription and activates the transcription factor Elk-1 in mature osteoclasts JO - Calcif. Tissue Int. VL - 76 UR - https://doi.org/10.1007/s00223-004-0099-8 DO - 10.1007/s00223-004-0099-8 ID - Yao2005 ER - TY - JOUR AU - Song, I. PY - 2009 DA - 2009// TI - Regulatory mechanism of NFATc1 in RANKL-induced osteoclast activation JO - FEBS Lett. VL - 583 UR - https://doi.org/10.1016/j.febslet.2009.06.047 DO - 10.1016/j.febslet.2009.06.047 ID - Song2009 ER -